Estrategia  antitrombótica en FA y PCI/STENT
 

Recomendación terapéutica

R.Pitarch-2010©©

Volver

CHA²DS²-VASc Score
CHADS2 Score
TIMI risck score
HANS-BLED Sangrado Score
 
VKA: Vitamina K antagonistas
PCI: Intervención Coronaria Percutanea
Riesgo tromboembolico evaluado con TIMI risck score si SCASEST
* si se utiliza AAS añadir IPP (omeprazol)

 

Adaptado de:The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) 2010: Guidelines for the management of atrial fibrillation
Bibliografia:Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, Kirchhof P, Marin F. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost 2010;103:13–28.